Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.76 |
| ▸ | TNKS | O95271 | 1/20 | 0.61 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.61 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393105 | 1.00 | PARP1 (0.76) | PARP1TNKSPARP6TNKS2PARP2 | |
| SCHEMBL15918004 | 0.91 | PARP1 (0.64) | PARP1TNKSPARP6TNKS2PARP2 | |
| SCHEMBL15917565 | 0.90 | PARP1 (0.83) | PARP1 | |
| SCHEMBL29390881 | 0.90 | PARP1 (0.83) | PARP1 | |
| SCHEMBL15918230 | 0.86 | PARP1 (1.00) | PARP1 | |
| SCHEMBL29390407 | 0.86 | PARP1 (1.00) | PARP1 | |
| SCHEMBL14233393 | 0.86 | PARP1 (0.80) | PARP1 | |
| SCHEMBL29392924 | 0.85 | PARP1 (0.77) | PARP1 | |
| SCHEMBL15918181 | 0.85 | PARP1 (0.77) | PARP1 | |
| SCHEMBL15919208 | 0.84 | PARP1 (1.00) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | claimed |
| EP-3925962-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | Rakovina Therapeutics Inc. (CA) | 2021-12-22 | — | — | EP | claimed |
| EP-2714703-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2021-03-10 | — | — | EP | claimed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | claimed |
| US-20170057984-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2017-03-02 | — | — | US | claimed |
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | claimed |
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | KANION USA INC. | 2023-01-26 | — | — | US | disclosed |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| EP-3925962-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE | Rakovina Therapeutics Inc. (CA) | 2021-12-22 | — | — | EP | disclosed |
| EP-2714703-B1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | RAKOVINA THERAPEUTICS INC. (CA) | 2020-09-24 | — | — | US | disclosed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170057984-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885TNKS 15/4885PARP6 12/4885 |
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885TNKS 15/4885PARP6 12/4885 |
| US-20170057984-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885TNKS 15/4885PARP6 12/4885 |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885TNKS 15/4885PARP6 12/4885 |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | PARP1 1/4885TNKS 15/4885PARP6 12/4885 |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | PARP1 1/4885TNKS 17/4885PARP6 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.